Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alliqua, a biomedical products company, has filed a provisional patent application with the US Patent and Trademark Office (USPTO) to enhance its transdermal delivery technology.
Subscribe to our email newsletter
The filing was based on positive test results with respect to specific chemical agents that improved the delivery of active ingredients when used in conjunction with the company’s hydrogel drug delivery platform.
Alliqua focuses on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation.
Through its subsidiary Alliqua BioMedical, Alliqua intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform of AquaMed Technologies.
AquaMed’s custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics uses proprietary manufacturing technologies which enable AquaMed to produce the healthcare industry as high water content, electron beam cross-linked aqueous polymer sheet hydrogels.
Alliqua Chairman David Stefansky said this patent filing is the second in a series of filings that they hope to continue as they develop additional improvements and processes.